The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours.
To assess the role of scintigraphy with 111In-DTPA-D-Phe-octreotide (111In-octreotide) in the diagnosis of pituitary adenomas and in the evaluation of post-surgical recurrent or residual tumours, we performed scintigraphy with 111In-DTPA-D-Phe-octreotide (SRS) in 35 patients: 14 patients with confirmed pituitary tumours and 15 with confirmed recurrent tumours. Clinical, biochemical and histological analyses, conventional images (CT/MRI), and follow-up assessments during a period of 1 year to 4 years were recorded in all patients. In the present study, scintigraphy with 111In-octreotide showed positive uptake in 10 out of 14 patients with confirmed pituitary tumour and in 13 out of 15 patients with confirmed recurrent tumour, with an overall sensitivity of 79%. SRS showed better results in growth hormone (GH)- and prolactin (PRL)-secreting tumours (7/8 patients correctly identified) than in other adenomas (3/9). SRS detected recurrence of adenocorticotrophic hormone (ACTH)-secreting tumours (4/5 patients correctly identified) and non-secreting tumours (5/7 patients correctly identified). 111In-octreotide scintigraphy, in combination with other imaging modalities, is useful in the diagnosis and follow-up of pituitary tumours. It allows scar tissue to be differentiated from tumour recurrence after surgical treatment and ensures better selection of patients who will benefit from medical treatment with somatostatin analogues.
Acosta-Gómez
M J
MJ
Department of Nuclear Medicine, Virgen de las Nieves Hospital, Avda. de las Fuerzas Armadas 2, 18014 Granada, Spain.
Muros
M A
MA
Llamas-Elvira
J M
JM
Ramírez
A
A
Ortega
S
S
Sabatel
G
G
Ramos
C
C
de la Riva-Aguilar
A
A
D000236:Adenoma / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000628:therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging*; D018365:Neoplasm, Residual; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000628:therapy; D011182:Postoperative Care; D011446:Prospective Studies; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D014057:Tomography, X-Ray Computed / Q000379:methods
C442550:(111)indium-DTPA-D-phe octreoide; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D004369:Pentetic Acid